| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 0.28 | 64.7% | 86.7% |
| Total Income | 0.28 | 64.7% | 86.7% |
| Expenditure | 6.55 | 2.8% | 8.5% |
| PBT | -6.31 | 0.8% | 10.5% |
| Net Profit | -6.31 | 0.5% | 7.1% |
| OPM | — | ||
| NPM | — | ||
| EPS | -1.01 | 30.8% | 531.3% |
Co-Diagnostics Reports Q3 2026 Financial Results
10 Nov 2026 · 10 Nov, 6:36 pm
Summary
Co-Diagnostics announced its financial results for the third quarter ended September 30, 2026, reporting revenue of $0.3 million, up from $0.1 million in the prior year's quarter. Operating expenses were reduced by 12% year-over-year to $6.2 million. The company reported a net loss of $6.3 million, or $1.01 per share, an improvement from the $4.66 loss per share in Q3 2025, primarily due to reduced operating expenses. Management highlighted significant regulatory and operational progress, including two regulatory submissions under review in India and the U.S., and the launch of its cloud and mobile infrastructure in India.
Key Highlights
- 1
Co-Diagnostics reported revenue of $0.3 million for the third quarter of 2026, an increase from $0.1 million in the third quarter of 2025.
- 2
Operating expenses decreased by 12% year over year to $6.2 million in the third quarter of 2026.
- 3
The net loss for the third quarter of 2026 was $6.3 million, or $1.01 per share, compared to a net loss of $5.9 million, or $4.66 per share, in the third quarter of 2025.
- 4
Adjusted EBITDA loss improved to $5.9 million in Q3 2026 from a loss of $6.3 million in Q3 2025.
- 5
The company submitted a 510(k) premarket notification and concurrent CLIA Waiver by Application to the FDA for the Co-Dx PCR Flu A/B & RSV test.
- 6
CoSara completed its clinical performance study for its point-of-care tuberculosis test and submitted it to India's CDSCO.
- 7
The company launched its integrated cloud and mobile infrastructure in India to support tuberculosis clinical work.
Management Comments
Dwight Egan
The third quarter was a period of significant regulatory and operational progress for Co-Diagnostics. CoSara completed its clinical performance study for our point-of-care tuberculosis test and submitted it to India’s Central Drugs Standard Control Organization (CDSCO), and together with our August FDA 510(k) submission for the Flu A/B & RSV test, we now have two regulatory submissions under review in two important markets for our platform. We also launched our cloud and mobile infrastructure in India, began evaluating blood-based testing with ReadyGo, and completed the first international deployment of Vector Smart. With our submissions in India and the U.S. under review, our focus is on supporting those reviews, advancing our feasibility work with ReadyGo and continuing to grow Vector Smart.
Informational and educational content only. Not investment advice.